
Pharma giant Pfizer, Inc. (NYSE:PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier. The company announced a deal Thursday to buy privately held biopharma ReViral, which has a portfolio of antiviral therapeutic candidates, for up to $525 million.
What's RSV: Respiratory syncytial virus, or RSV, is a common respiratory virus causing mild, cold-like symptoms, according to the Centers for Disease Control and Prevention.